Pax-9 Double Nickase Plasmid (h): sc-403899-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Pax-9 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Pax-9 Double Nickase Plasmid (h) and Pax-9 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PAX9. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Pax-9 Antibody (7C2): sc-56823
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pax-9 Double Nickase Plasmid (h) | sc-403899-NIC | 20 µg | $410.00 | |||
Pax-9 Double Nickase Plasmid (h2) | sc-403899-NIC-2 | 20 µg | $410.00 |
PAX9 encodes the paired box transcription factor Pax-9, a nuclear DNA-binding regulator that controls lineage specification and organogenesis programs during embryonic development. Pax-9 participates in transcriptional networks governing epithelial–mesenchymal interactions, craniofacial patterning, and odontogenesis by modulating downstream developmental gene expression. Altered PAX9 dosage or sequence variants are linked to congenital tooth agenesis and broader craniofacial developmental phenotypes, making it a useful locus for studying gene regulatory circuitry. In cancer biology, dysregulated PAX9 expression has been investigated in the context of differentiation state and tissue-specific transcriptional remodeling.
Pax-9 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PAX9 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PAX9. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PAX9 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PAX9-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.